JDRF backs Defymed for artificial pancreas study
French biotech developer Defymed said today that it is partnering with the Junior Diabetes Research Foundation to fund studies of the company’s Mailpan bioartifical pancreas. The Mailpan device is...
View ArticleDefymed partners with Semma Therapeutics on bio-artificial pancreas
French biotech developer Defymed said today it inked a collaborative deal with American biotech company Semma Therapeutics to support the continued development of a bio-artificial pancreas to treat...
View ArticleArtificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial...
View ArticleDefymed reveals development of novel insulin delivery device
France-based medtech company Defymed said today that it’s developing a novel insulin delivery device which it hopes to bring to market by the end of 2020. The company’s device, ExOlin, uses a...
View Article
More Pages to Explore .....